Keywords
Breast cancer
HER2
Brain metastases
HER2
Brain metastases
How to Cite
Edirappuli, S. ., & Bedowes, E. (2019). Effects of Various Treatment Regimens on the Survival of HER2-positive Breast Cancer Patients with Brain Metastasis . The Physician, 6(1), c12. https://doi.org/10.38192/1.6.1.c12
Abstract
Overexpression of HER2 (human epidermal growth factor receptor 2) occurs in around 20% of breast cancers. This particular subtype is known to be very aggressive and had the worst prognosis prior to the introduction of targeted therapy. The development of anti-HER2 therapies such as trastuzumab and pertuzumab has shown to dramatically improve the prognosis of patients with HER2-positive breast cancer.
References
Peer reviewed by Sunil Daga PhD MRCP & Subarna Chakravorty PhD FRCPath for BAPIO Annual Conference, London 2019
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2019 Array